A modular synthetic promoter toolkit for programmable gene control in activated and chronically stimulated T cells
Synthetic circuits that couple transgene expression to endogenous transcription factor (TF) activity enable cellular response to changing functional states. In T cells, antigen stimulation results in dynamic changes of transcription factor expression programs. Harnessing these endogenous TF dynamics for programmable gene control remains an important challenge in engineered T cells. Here, we develop a library of synthetic promoters (SPs) responsive to seven TFs identified through transcriptomic analysis of T-cell activation programs. These promoters couple endogenous TF activity to transcriptional output across a broad dynamic range of inducibility and basal expression. We quantitatively profile promoter performance in HEK293 and Jurkat cells, evaluate them for orthogonality, and integrate them into Boolean logic gate architectures and network topologies to minimize basal transcriptional leakiness and improve ON/OFF ratios. We test selected synthetic promoters in primary human CD8⁺ T cells, under endogenous TF regulation, and we further characterize the NR4A2-responsive promoter subset in vitro and in tumor-infiltrating engineered T cells in a melanoma xenograft model, demonstrating dynamic and reversible activation.Together, these results provide a modular SP toolkit of TF-responsive synthetic promoters for programmable transcriptional control in engineered T cells. Achieving programmable gene regulation remains a challenge for engineering T cells. Here the authors characterize a library of synthetic promoters, responsive to seven endogenous T cell transcription factors, that show broad dynamic range of inducibility and basal expression.
Authors
- Loris Melchiorri
- Caio Raony Farina Silveira (ORCID: https://orcid.org/0000-0001-5778-7789)
- Giuliano Bonfá (ORCID: https://orcid.org/0000-0003-2257-5502)
- Christoph Heuser (ORCID: https://orcid.org/0000-0003-1410-7573)
- Timea Vadász (ORCID: https://orcid.org/0000-0001-8570-7125)
- Rita Tarnai (ORCID: https://orcid.org/0009-0007-5049-9099)
- D Perna
- Luca Gattinoni (ORCID: https://orcid.org/0000-0003-2239-3282)
- F. Piro (ORCID: https://orcid.org/0009-0009-7865-2037)
- Fabiana Tedeschi
- Juan Luis Blazquez-Roman
- Fabio Caliendo (ORCID: https://orcid.org/0000-0002-5676-6000)
- Assunta Sellitto (ORCID: https://orcid.org/0000-0002-6555-2362)
- Filippo Menolascina (ORCID: https://orcid.org/0000-0002-4937-7912)
- Antonio Rinaldi (ORCID: https://orcid.org/0000-0001-8854-6048)
- Freddie Starkey
- Velia Siciliano (ORCID: https://orcid.org/0000-0001-7734-9153)
- Fabio Mastrogiovanni
- Giovanna Martino (ORCID: https://orcid.org/0009-0008-6928-6648)
- Evangelos Nikolados
Institutions
- University Hospital Bonn (DE)
- Center for Advanced Biomaterials for Healthcare (IT)
- Leibniz Institute for Immunotherapy
- University of Regensburg (DE)
- Massachusetts Institute of Technology (US)
- University of Naples Federico II (IT)
- University of Edinburgh (GB)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-09-16
- DOI
- https://doi.org/10.1038/s41467-026-77730-7
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Massachusetts Institute of Technology
- Università degli Studi di Napoli Federico II
- University of Edinburgh
- Associazione Italiana per la Ricerca sul Cancro
- Universität Regensburg
- Istituto Italiano di Tecnologia
- Leibniz-Gemeinschaft